Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

Y0000370

Risperidone for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Risperidone, R 64,766

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C23H27FN4O2
Numero CAS:
106266-06-2
Peso molecolare:
410.48
Numero MDL:
MFCD00274576
Codice UNSPSC:
41116107
ID PubChem:
329830925
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

risperidone

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1

InChI

1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
RAPZEAPATHNIPO-UHFFFAOYSA-N

Informazioni sul gene

human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Risperidone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

1604665

Risperidone System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

R1000600

Risperidone, European Pharmacopoeia (EP) Reference Standard

1604654

Risperidone, United States Pharmacopeia (USP) Reference Standard

1604676

Risperidone Related Compounds Mixture, United States Pharmacopeia (USP) Reference Standard

Y0001276

Risperidone impurity K, European Pharmacopoeia (EP) Reference Standard

1604756

Risperidone Related Compound G, United States Pharmacopeia (USP) Reference Standard

PHR1631

Risperidone, Pharmaceutical Secondary Standard; Certified Reference Material

BP1137

Risperidone, British Pharmacopoeia (BP) Reference Standard

BP1158

Risperidone impurity standard, British Pharmacopoeia (BP) Reference Standard

Pittogrammi

Skull and crossbones
GHS06

Avvertenze

Danger

Indicazioni di pericolo

H301

Consigli di prudenza

P301 + P330 + P331 + P310

Classi di pericolo

Acute Tox. 3 Oral

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Vina M Goghari et al.
Schizophrenia research, 149(1-3), 149-155 (2013-07-09)
Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study
W Victor R Vieweg et al.
Psychopharmacology, 228(4), 515-524 (2013-07-03)
A recent publication asserted that even low-dose risperidone may induce corrected QT (QTc) interval prolongation up to 500 ms without drug-induced IKr blockade. We seek to better understand the complexity of any link between risperidone-induced/associated QTc interval prolongation and torsade de
Andrea Fagiolini et al.
Expert opinion on pharmacotherapy, 11(10), 1727-1740 (2010-05-22)
It is very rare for patients with bipolar disorder to have a single episode of mania or depression over a lifetime and the vast majority of these individuals need long-term prophylactic/maintenance treatment. However, treatment nonadherence is a major issue for
Jérôme A J Becker et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(9), 2049-2060 (2014-03-13)
The etiology of Autism Spectrum Disorders (ASDs) remains largely unknown. Identifying vulnerability genes for autism represents a major challenge in the field and allows the development of animal models for translational research. Mice lacking the mu opioid receptor gene (Oprm1(-/-))
Yvonne Freund-Levi et al.
Dementia and geriatric cognitive disorders, 38(3-4), 234-244 (2014-06-28)
To examine the effects of galantamine and risperidone on agitation in patients with dementia. A total of 100 patients with dementia and neuropsychiatric symptoms (mean age ± SD: 78.6 ± 7.5 years; 67% female) were included in this 12-week, randomized
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.